Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : AdhexPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
After 5-Year Delay, Cmc Pharmaceutical Wins FDA Nod for Oral Schizophrenia Drug
Details : Mezofy (aripiprazole) works as a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors, for treating schizophrenia.
Product Name : Mezofy
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2025
Lead Product(s) : Aripiprazole
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : AdhexPharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Study Phase : IND Enabling
Sponsor : US Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
Details : The funding will support the continued development of a promising medical countermeasure for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolamine.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 12, 2022
Lead Product(s) : Atropine Sulfate,Scopolamine
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : IND Enabling
Sponsor : US Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Undisclosed
Sponsor : US Department of Defense
Deal Size : Undisclosed
Deal Type : Funding
CMC Pharmaceuticals Awarded SBIR Grant for Concentrated Atropine Formulation
Details : The Phase I SBIR award will fund the formulation and analytical development of a concentrated Atropine Sulfate Drug Product with the aim to aid the military in treating organophosphate poisoning in service members.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 04, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Undisclosed
Sponsor : US Department of Defense
Deal Size : Undisclosed
Deal Type : Funding